全世界约有3000例病人使用 IL-2治疗,Rosenberg 小组已治疗483例,并见肿瘤(特别是转移性黑色素瘤及肾细胞癌)明显消退。Rosenberg 等通过动物试验证实有效率与IL-2剂量有关,以及 LAK 细胞再输注可大大增加 IL-2作用。Rosenberg 已报告180例转移性肾细胞癌用 LAN+IL-2及单用 IL-2治疗的随机研究结果,单用 IL-2组客观有效(病变缩小50%以上)率为20%,而加用LAK 细胞组为30%,临床完全缓解亦只见 About 3,000 patients worldwide have been treated with IL-2, and Rosenberg’s team has treated 483 and has seen significant regression of tumors (especially metastatic melanoma and renal cell carcinoma). Rosenberg et al. demonstrated that the efficacy is related to the dose of IL-2 by animal experiments, and the reinfusion of LAK cells can greatly increase the effect of IL-2. Rosenberg has reported a randomized study of 180 cases of metastatic renal cell carcinoma treated with LAN+IL-2 and IL-2 alone. The objective and effective use of the IL-2 group (with lesions reduced by more than 50%) was 20%. With LAK cell group 30%, complete clinical remission was also seen